S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News

$15.21
-0.08 (-0.52 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.84
Now: $15.21
$15.21
50-Day Range
$13.88
MA: $15.77
$19.21
52-Week Range
$10.63
Now: $15.21
$26.67
Volume1,725 shs
Average Volume152,344 shs
Market Capitalization$500.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More
Crinetics Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 million
Book Value$4.84 per share

Profitability

Net Income$-50,420,000.00

Miscellaneous

Employees47
Market Cap$500.17 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$15.21
-0.08 (-0.52 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

How has Crinetics Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRNX stock has decreased by 1.9% and is now trading at $15.21.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Crinetics Pharmaceuticals
.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02.
View Crinetics Pharmaceuticals' earnings history
.

What price target have analysts set for CRNX?

3 Wall Street analysts have issued twelve-month price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $38.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
.

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

News coverage about CRNX stock has trended somewhat negative on Friday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Crinetics Pharmaceuticals
.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,540,000 shares, an increase of 84.1% from the June 15th total of 1,380,000 shares. Based on an average daily trading volume, of 245,200 shares, the days-to-cover ratio is presently 10.4 days. Approximately 10.6% of the shares of the company are sold short.
View Crinetics Pharmaceuticals' Short Interest
.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Immunomedics (IMMU), Myovant Sciences (MYOV), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Chiasma (CHMA), Fulcrum Therapeutics (FULC), G1 Therapeutics (GTHX) and Karyopharm Therapeutics (KPTI).

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Versant Venture Management LLC (6.18%), 5AM Venture Management LLC (4.15%), Driehaus Capital Management LLC (2.70%), Point72 Asset Management L.P. (1.20%) and Bank of New York Mellon Corp (0.57%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Richard Scott Struthers, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals
.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, and Jacobi Capital Management LLC. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Richard Scott Struthers, and Vivo Capital Viii, Llc.
View insider buying and selling activity for Crinetics Pharmaceuticals
.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was purchased by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, FMR LLC, Driehaus Capital Management LLC, Point72 Asset Management L.P., Bank of New York Mellon Corp, California Public Employees Retirement System, Virtus ETF Advisers LLC, and Swiss National Bank.
View insider buying and selling activity for Crinetics Pharmaceuticals
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $15.21.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $500.17 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.